Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer - PubMed

Affiliations

• PMID: 14639613
• DOI: 10.1002/ijc.11544

Comparative Study

Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer

Annekatrin Lukanova et al. Int J Cancer. 2004.

Abstract

Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer.

Similar articles

• Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.

  Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E. Kaaks R, et al. J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600. doi: 10.1093/jnci/92.19.1592. J Natl Cancer Inst. 2000. PMID: 11018095

• Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer.

  Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE, Peeters PH. Keinan-Boker L, et al. Int J Cancer. 2003 Aug 10;106(1):90-5. doi: 10.1002/ijc.11193. Int J Cancer. 2003. PMID: 12794762

• Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.

  Lacey JV Jr, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, Sherman ME, Brinton LA. Lacey JV Jr, et al. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15066926

• Obesity and breast cancer in premenopausal women: Current evidence and future perspectives.

  Laudisio D, Muscogiuri G, Barrea L, Savastano S, Colao A. Laudisio D, et al. Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:217-221. doi: 10.1016/j.ejogrb.2018.03.050. Epub 2018 Mar 27. Eur J Obstet Gynecol Reprod Biol. 2018. PMID: 29730021 Review.

• Does IGF-1 play a role in the biology of endometrial cancer?

  Majchrzak-Baczmańska D, Malinowski A. Majchrzak-Baczmańska D, et al. Ginekol Pol. 2016;87(8):598-604. doi: 10.5603/GP.2016.0052. Ginekol Pol. 2016. PMID: 27629137 Review.

Cited by

• A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.

  Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. Gunter MJ, et al. Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):921-9. doi: 10.1158/1055-9965.EPI-07-2686. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18398032 Free PMC article.

• Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

  Joehlin-Price AS, Stephens JA, Zhang J, Backes FJ, Cohn DE, Suarez AA. Joehlin-Price AS, et al. Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):438-45. doi: 10.1158/1055-9965.EPI-15-1145. Epub 2015 Dec 18. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26682991 Free PMC article.

• Association of coffee and caffeine consumption with risk and prognosis of endometrial cancer and its subgroups: a Mendelian randomization.

  Chen Z, Liu C, Wu J, Kong F. Chen Z, et al. Front Nutr. 2023 Nov 14;10:1291355. doi: 10.3389/fnut.2023.1291355. eCollection 2023. Front Nutr. 2023. PMID: 38035346 Free PMC article.

• IGF-1 receptor inhibitors in clinical trials--early lessons.

  Weroha SJ, Haluska P. Weroha SJ, et al. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-83. doi: 10.1007/s10911-008-9104-6. Epub 2008 Nov 21. J Mammary Gland Biol Neoplasia. 2008. PMID: 19023648 Free PMC article. Review.

• The Association between Polymorphismsin Insulin and Obesity Related Genesand Risk of Colorectal Cancer.

  Rezaei-Tavirani M, Safaei A, Zali MR. Rezaei-Tavirani M, et al. Iran J Cancer Prev. 2013 Fall;6(4):179-85. Iran J Cancer Prev. 2013. PMID: 25250132 Free PMC article. Review.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

• Full Text Sources

  • Wiley

• Miscellaneous

  • NCI CPTAC Assay Portal